These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30146390)

  • 1. Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane.
    Jin J; Galaz-Montoya JG; Sherman MB; Sun SY; Goldsmith CS; O'Toole ET; Ackerman L; Carlson LA; Weaver SC; Chiu W; Simmons G
    Cell Host Microbe; 2018 Sep; 24(3):417-428.e5. PubMed ID: 30146390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
    Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response.
    Her Z; Teng TS; Tan JJ; Teo TH; Kam YW; Lum FM; Lee WW; Gabriel C; Melchiotti R; Andiappan AK; Lulla V; Lulla A; Win MK; Chow A; Biswas SK; Leo YS; Lecuit M; Merits A; Rénia L; Ng LF
    EMBO Mol Med; 2015 Jan; 7(1):24-41. PubMed ID: 25452586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity.
    Lum FM; Couderc T; Chia BS; Ong RY; Her Z; Chow A; Leo YS; Kam YW; Rénia L; Lecuit M; Ng LFP
    Sci Rep; 2018 Jan; 8(1):1860. PubMed ID: 29382880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking the Exit: CHIKV Neutralizing Antibodies Nip Viral Egress in the Bud.
    McCarthy MK; Morrison TE
    Cell Host Microbe; 2018 Sep; 24(3):328-330. PubMed ID: 30212644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chikungunya-specific IgG and neutralizing antibody responses in natural infection of Chikungunya virus in children from India.
    Verma A; Nayak K; Chandele A; Singla M; Ratageri VH; Lodha R; Kabra SK; Murali-Krishna K; Ray P
    Arch Virol; 2021 Jul; 166(7):1913-1920. PubMed ID: 33907861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
    Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
    MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A chikungunya fever vaccine utilizing an insect-specific virus platform.
    Erasmus JH; Auguste AJ; Kaelber JT; Luo H; Rossi SL; Fenton K; Leal G; Kim DY; Chiu W; Wang T; Frolov I; Nasar F; Weaver SC
    Nat Med; 2017 Feb; 23(2):192-199. PubMed ID: 27991917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Neutralization Assay Using an eGFP Chikungunya Virus.
    Deng CL; Liu SQ; Zhou DG; Xu LL; Li XD; Zhang PT; Li PH; Ye HQ; Wei HP; Yuan ZM; Qin CF; Zhang B
    Viruses; 2016 Jun; 8(7):. PubMed ID: 27367716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of Chikungunya virus inhibition by monoclonal antibodies.
    Zhou QF; Fox JM; Earnest JT; Ng TS; Kim AS; Fibriansah G; Kostyuchenko VA; Shi J; Shu B; Diamond MS; Lok SM
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27637-27645. PubMed ID: 33087569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.
    Goo L; Dowd KA; Lin TY; Mascola JR; Graham BS; Ledgerwood JE; Pierson TC
    J Infect Dis; 2016 Nov; 214(10):1487-1491. PubMed ID: 27655868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chikungunya Virus Fidelity Variants Exhibit Differential Attenuation and Population Diversity in Cell Culture and Adult Mice.
    Riemersma KK; Steiner C; Singapuri A; Coffey LL
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neutralizing role of IgM during early Chikungunya virus infection.
    Chua CL; Sam IC; Chiam CW; Chan YF
    PLoS One; 2017; 12(2):e0171989. PubMed ID: 28182795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of neutralizing antibodies produced by papaya mosaic virus nanoparticles fused to the E2EP3 peptide epitope of Chikungunya envelope.
    Nor Rashid N; Teoh TC; Al-Harbi SJ; Yusof R; Rothan HA
    Trop Biomed; 2021 Mar; 38(1):36-41. PubMed ID: 33797522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chikungunya virus glycoproteins pseudotype with lentiviral vectors and reveal a broad spectrum of cellular tropism.
    Hu D; Zhang J; Wang H; Liu S; Yu L; Sun L; Qu Y
    PLoS One; 2014; 9(10):e110893. PubMed ID: 25333782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease Resolution in Chikungunya-What Decides the Outcome?
    Srivastava P; Kumar A; Hasan A; Mehta D; Kumar R; Sharma C; Sunil S
    Front Immunol; 2020; 11():695. PubMed ID: 32411133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high-throughput screening assay to identify inhibitory antibodies targeting alphavirus release.
    Ramjag A; Cutrone S; Lu K; Crasto C; Jin J; Bakkour S; Carrington CVF; Simmons G
    Virol J; 2022 Oct; 19(1):170. PubMed ID: 36309730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.
    Jin J; Liss NM; Chen DH; Liao M; Fox JM; Shimak RM; Fong RH; Chafets D; Bakkour S; Keating S; Fomin ME; Muench MO; Sherman MB; Doranz BJ; Diamond MS; Simmons G
    Cell Rep; 2015 Dec; 13(11):2553-2564. PubMed ID: 26686638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins.
    Quiroz JA; Malonis RJ; Thackray LB; Cohen CA; Pallesen J; Jangra RK; Brown RS; Hofmann D; Holtsberg FW; Shulenin S; Nyakatura EK; Durnell LA; Rayannavar V; Daily JP; Ward AB; Aman MJ; Dye JM; Chandran K; Diamond MS; Kielian M; Lai JR
    PLoS Pathog; 2019 Nov; 15(11):e1008061. PubMed ID: 31697791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
    Weber C; Büchner SM; Schnierle BS
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003684. PubMed ID: 25905779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.